Comparative guide · 6 min read

Saffron vs St. John's Wort for mild-to-moderate depression — which one for which patient?

Updated 2026-05-18 · Reviewed by SupplementScore editors · No sponsorships

These two are the most-studied botanical antidepressants in the supplement world, and both reach effect sizes comparable to first-line SSRIs in trials of mild-to-moderate (not severe) depression. The choice almost always comes down to drug interactions, not efficacy. St. John's Wort is a notorious CYP3A4 inducer with a long list of clinically important interactions; saffron has a much cleaner interaction profile, and a meaningfully better safety story for patients on other medications.

Quick verdict

Patient situationBetter choiceWhy
Mild-to-moderate depression, no other medsEither; saffron has simpler interaction profileBoth reach moderate effect sizes in trials; saffron is easier to layer.
On hormonal contraceptionSaffronSt. John's Wort lowers ethinyl-estradiol levels — documented contraceptive failures.
On any HIV antiviral, transplant immunosuppressant, or warfarinSaffronSt. John's Wort is contraindicated — induces multiple metabolic enzymes.
Comorbid mild anxietySaffronTrial signal in anxiety endpoints; St. John's Wort effect on anxiety is more variable.
Premenstrual depressive symptoms (PMS/PMDD)SaffronSpecific RCT evidence; St. John's Wort has mixed PMS evidence.
Sleep-onset insomnia + low moodSaffronAffron-brand saffron has a sleep-quality trial signal.
Photosensitive skin / occupational sun exposureSaffronSt. John's Wort can cause clinically meaningful photosensitivity.
Severe depression or suicidalityNeither — seek prescriberBotanicals are appropriate adjuncts at most; not for severe disease.

How they compare on the things that matter

Mechanism — multiple monoaminergic actions, both

Saffron's antidepressant effects are attributed to crocins, crocetin, and safranal — carotenoid-class compounds that appear to inhibit serotonin reuptake, modulate dopamine and norepinephrine, and reduce HPA-axis activation. The Affron-brand standardised extract (3.5% lepticrosalides) has most of the modern RCT weight.

St. John's Wort (Hypericum perforatum) contains hypericin, hyperforin, and a complex flavonoid profile. Hyperforin is the principal antidepressant constituent — it inhibits reuptake of serotonin, norepinephrine, dopamine, GABA, and glutamate, and is the cause of the drug-interaction problem because it potently induces CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein.

Evidence base by endpoint

Practical rule. Efficacy is similar; the deciding factor is medication context. Anyone on hormonal contraception, HIV antivirals, transplant immunosuppressants, warfarin, digoxin, or many cancer chemotherapies should not take St. John's Wort. For most people on those medications — and for adults who want a low-interaction-risk option — saffron (Affron 28 mg/day or generic saffron 30 mg/day) is the safer first choice. Both warrant a 6–8 week trial with a clear stopping rule.

Dose and form

For saffron, Affron at 28 mg/day or generic standardised saffron extract at 30 mg/day (typically split morning and evening) has the cleanest trial support. Standardisation to 2% safranal or 3.5% lepticrosalides is preferable to raw saffron threads at supplement scale.

For St. John's Wort, standardised LI 160 or WS 5570 at 300 mg t.i.d. (900 mg total) has the most RCT weight. Standardisation to 0.3% hypericin (older standard) or 3% hyperforin (newer; hyperforin is the active antidepressant) matters — products vary widely.

Safety

Saffron is well-tolerated at supplement doses. Most common adverse effects are mild GI upset and headache. At very high doses (5+ g — far above supplement dosing), saffron has uterotonic effects and is contraindicated in pregnancy. Avoid combination with serotonergic medications without prescriber oversight (theoretical serotonin syndrome risk).

St. John's Wort has a serious interaction profile due to CYP3A4 induction. Documented clinically important interactions include: oral contraceptives (failure reported), warfarin (reduced INR), digoxin (reduced levels), cyclosporine and tacrolimus (transplant rejection reported), HIV protease inhibitors and NNRTIs (virologic failure), many chemotherapies (reduced efficacy), SSRIs and triptans (serotonin syndrome), and others. Photosensitivity is dose-dependent. Pregnancy and breastfeeding safety data are inadequate; avoid.

What the price difference buys you

Affron saffron at 28 mg/day runs $0.60–1.20/day. Generic saffron at 30 mg/day runs $0.40–0.80/day. St. John's Wort at 900 mg/day runs $0.20–0.40/day. St. John's Wort is the cheaper supplement, but the interaction cost (medication changes, contraceptive failure risk) can be high in patients on other drugs.

Who should skip each

Saffron should be approached cautiously in pregnancy (avoid medicinal doses), in users on serotonergic medications (SSRIs, SNRIs, triptans, MAOIs, tramadol) without prescriber oversight, and in users on warfarin (theoretical antiplatelet effect at higher doses).

St. John's Wort should be avoided in: pregnancy and breastfeeding, users on hormonal contraception, users on any HIV antiviral, users on transplant immunosuppressants, users on warfarin or DOACs, users on digoxin, users on most chemotherapy, users on SSRIs/SNRIs/triptans/MAOIs, users with bipolar disorder (mania risk), and users with photosensitive skin disease.

What we'd actually buy

For most adults with mild-to-moderate depression and an awareness of the medication-interaction landscape: Affron saffron 28 mg/day for 8 weeks, with a clear improvement endpoint (PHQ-9 self-rating weekly). If no improvement at 8 weeks, the supplement is not the rate-limiting input — escalate to clinician evaluation.

For adults with no concurrent medications and a careful read of the long contraindication list above, St. John's Wort WS 5570 at 900 mg/day is reasonable. Hand this article to a prescriber before starting if there is any active medication.

Sources

Read more: